It is an effective option for patients who prefer an oral medication or for whom injectable GLP-1 therapy is not appropriate
These methods can help sustain adequate B12 levels and are often more convenient for long-term use
As we look ahead, here are a couple of key developments to watch for that will expand your future options: More Approved Oral Versions: Expect the FDA to approve new oral medications, including higher doses of existing drugs and entirely new compounds like Orforglipron
Together, we can explore the best strategies to enhance your health and quality of life
One study evaluated semaglutide for weight loss in obese women with PCOS who had not responded to lifestyle changes: Almost 80% of participants achieved a weight loss of at least 5%
Clinical trials have demonstrated average weight loss of approximately 15% with semaglutide, 2022% with tirzepatide, and over 24% with retatrutide over the course of treatment